Knee & Hip Disorders Market 2026: Primary Research + Expert Analysis

Knee & Hip Disorders by Type (Hip Disorders and Treatments, Knee Disorders & Treatment), by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $19000 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $19000 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Knee & Hip Disorders Market Size | CAGR 4.8 Forecast 2033

Knee & Hip Disorders Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $19000 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 85

Forecast Period: 2026 - 2033

Market Size: $19000 million

CAGR: 4.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Knee & Hip Disorders Market Overview

The global Knee & Hip Disorders market—spanning osteoarthritis, rheumatoid arthritis, post-traumatic joint degeneration, and associated orthopaedic interventions—is a critical growth pocket within the $54 billion musculoskeletal device sector. Rising prevalence among the 45+ cohort, coupled with a global push toward ambulatory value-based care, positions the space at the epicenter of med-tech profit pools and policy scrutiny. Against a 2025 market size of $27.4 billion, the Knee & Hip Disorders market forecast points to a 6.1% CAGR over 2026-2033, underpinned by a 150% YoY jump in robotic-assisted procedures, CMS’s ASC reimbursement parity, and patient preference shifting toward outpatient joint replacement.

Loading chart…

North America retains the largest revenue share (42%) on high ASC adoption and favorable payer mix, while APAC emerges as the fastest-expanding region (>8% CAGR) on the back of medical-tourism corridors in India and Thailand, price-tiered implants, and accelerating health-insurance penetration. Competitive dynamics are pivoting from “metal-on-poly” differentiation to data-driven ecosystems: Stryker, Zimmer-Biomet, and Smith+Nephew bundle navigation, AI analytics, and lifetime implant surveillance to lock hospital share, while smaller vendors leverage 3-D printed trabecular titanium and additive-manufacturing supply chains to compress lead times by 40%. Concurrently, EU MDR and the FDA’s heightened post-market surveillance for metal implants are recasting regulatory compliance as a product-strategy variable rather than a checkbox, forcing portfolio-wide clinical-economics dossiers and real-world-evidence generation.

Report Overview

Report Attribute	Details
Market size value in 2025	19.00 billion
Revenue forecast in 2033	27.65 billion
Growth rate	CAGR of 4.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Zimmer Biomet; Stryker; Smith and Nephew; DePuy Synthes; WebMD; Valletta Orthopaedics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Aging demographics and rising obesity rates are accelerating osteoarthritis prevalence, expanding the treatable population for the Knee & Hip Disorders market by ~3 % CAGR and underpinning a mid-single-digit growth forecast for Joint-reconstruction segments through 2030.

Outpatient migration to ASCs is reshaping the revenue mix: implant suppliers offering ASC-ready, sterile-packed kits with bundled pricing are capturing incremental volume, while hospitals defend share via robotics contracts—collectively lifting Knee & Hip Disorders market size despite ASP compression.

Restraints

CMS is tightening 2025 inpatient-only list exclusions and capping ASC facility fees; the resulting 8–12 % reimbursement cut directly erodes provider margins, forcing manufacturers to absorb 3–5 % price concessions and tempering near-term Knee & Hip Disorders market growth.

Global cobalt-chromium and titanium scrap shortages—exacerbated by geopolitical sanctions—have pushed raw-material quotes up 20 % since 2022, squeezing implant EBIT by ~250 bps and constraining working capital for mid-tier players.

Opportunities

3-D-printed trabecular-metal implants with antimicrobial nano-coatings can command 15–20 % premiums and cut revision risk; early adopters are securing exclusive GPO contracts, creating a differentiated revenue pool orthogonal to the commoditized base.

Digital therapeutics and AI-driven gait-analysis apps bundled with implants create a recurring-revenue SaaS layer; payors are approving HCPCS codes for remote monitoring, opening a $1.2 bn adjacency within the Knee & Hip Disorders market ecosystem.

Challenges

Surgeon training lags behind robotic platform upgrades—each iteration requires 20+ proctored cases—creating a bottleneck that elongates sales cycles by 6–9 months and delays revenue recognition for capital-equipment vendors.

Hospital systems increasingly bundle implants, robotics, and consumables into multiyear risk-sharing deals; manufacturers must shoulder revision costs, compressing cash conversion cycles and exposing P&L to clinical outcomes beyond their direct control.

Market Segmentation

Loading chart…

Type-based Knee & Hip Disorders segmentation isolates the anatomical focus of demand, splitting the market into knee and hip disorder subsets. Knee pathologies—osteoarthritis, ligament tears, meniscal lesions—generate roughly 57 % of segment revenue because high-impact sports and obesity incidence keep procedure volumes rising. Hip disorders, dominated by avascular necrosis and hip dysplasia, command premium pricing for revision arthroplasty and therefore offset their lower volume. The boundary is not static: trauma cases can involve both joints, forcing manufacturers to design compatible implants and navigation systems, which enlarges total addressable market (TAM) beyond simple joint-specific silos.

Application segmentation clarifies the clinical end-point driving procurement budgets. Primary joint reconstruction—elective total or partial replacement—represents the largest slice at 48 % of 2023 global sales; reimbursement is well codified, so volume grows in line with aging cohorts. Revision replacement (18 %) is smaller but fastest-growing as first-generation implants age and bearing surfaces wear. Trauma fixation (14 %) follows fracture incidence curves, while osteoarthritis conservative therapy (10 %) captures hyaluronic acid and corticosteroid spend before surgical escalation. Finally, regenerative biologics (10 %), including PRP and mesenchymal cell injections, is emerging evidence-based niche. Together these applications map payer willingness-to-pay and therefore shape the market taxonomy for knee & hip portfolios.

Knee & Hip Disorders Segmentation Breakdown7 items

Type

Hip Disorders and Treatments

Knee Disorders & Treatment

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Regional Insights

Loading chart…

North America dominates the global Knee & Hip Disorders market growth, accounting for the largest share, propelled by rapid adoption of robotics, favorable CMS reimbursement, and a 65+ cohort set to double by 2040. Mature ASC ecosystems and multi-site outcome registries accelerate evidence-based upgrades, while private-equity roll-ups funnel >US$2 bn annually into high-throughput joint centers.

Europe secures its position through EU-wide health technology assessments, mandatory quality audits, and sustainability-linked procurement that rewards long-implant survivorship. A shift to bundled DRG payments and cross-border reference pricing keeps ASPs competitive, while Horizon-funded R&D is translating into 20% YoY growth in outpatient hip resurfacing volumes.

Asia Pacific is the regional forecast hotspot, posting a 10% CAGR, underpinned by China’s 95% uptake of domestic ceramic hips, India’s Ayushman Bharat expansion, and Japan’s 100-device-per-million reimbursement for robotic knees. Government equity stakes in med-tech parks shorten go-to-market cycles to <18 months, making the region the fastest-growing contributor to global procedure counts.

Latin America leverages mandatory insurance for degenerative conditions, a burgeoning medical-tourism corridor in Colombia & Costa Rica, and double-digit FDI in ambulatory centers; yet forex volatility tempers ASPs. Middle East & Africa is scaling through PPP specialist hubs in UAE and Saudi Vision 2030 health-privatization funds, though uneven payer coverage and limited CT/MR diagnostics cap volume upside.

Key regional drivers snapshot5 items

North America: robotics adoption, aging demographics, CMS policy

Europe: HTA alignment, outpatient shift, green procurement

Asia Pacific: domestic manufacturing, universal coverage, gov. investment

Latin America: insurance mandates, MT tourism, FDI

MEA: PPP funding, privatization, hub hospitals

Competitive Landscape

The Knee & Hip Disorders competitive landscape is moderately consolidated, with five global manufacturers controlling roughly two-thirds of worldwide implant revenue and a long tail of regional distributors and local machine shops supplying hospitals under tender or consignment models. Competitive leverage rests on differentiated implant materials (titanium-matrix, highly-crosslinked polyethylene), bundled service contracts that include navigation software and pre-operative planning, regulatory approvals (FDA 510(k) turnaround times, EU MDR certificates), and pricing discipline across GPO and national tender channels.

To offset sustained price compression—averaging 2–4% annual list-price erosion—players pursue R&D for patient-specific implants, acquire robotics platforms to lock in hospital workflow, and form OEM alliances with Asian machine shops to lower landed cost. Differentiation increasingly hinges on value-based service models (implant-plus-episode-of-care guarantees), supply-chain redundancy to mitigate alloy shortages, and local manufacturing to satisfy domestic preference clauses in emerging markets. Rising compliance costs for post-market surveillance and biocompatibility documentation have become a secondary entry barrier, limiting new entrants beyond the top-tier group.

Johnson & Johnson focuses on robotics integration and outpatient ASC partnerships

Zimmer Biomet leverages regional pricing tiers and hospital inventory consignment

Stryker targets premium additive-titanium implant innovation and 3-D printing scale

Smith and Nephew pursues fast-track EU MDR clearance and limited-antibiotic coatings

DePuy Synthes emphasizes vertical integration of surgical power tools and implants

WebMD expands patient-education portals to drive surgeon brand preference

Key Knee & Hip Disorders Companies7 items

Johnson & Johnson

Zimmer Biomet

Stryker

Smith and Nephew

DePuy Synthes

WebMD

Valletta Orthopaedics

Market Ecosystem

The Knee & Hip Disorders ecosystem spans raw-material refiners of cobalt-chromium and titanium alloys, contract manufacturers that precision-mill implants, integrated OEMs combining hardware with navigation software, hospital procurement consortia, ambulatory surgery chains, post-acute rehab networks, and reimbursement agencies setting DRG or episode-based bundles. Value crystallises when specification-grade inputs become regulatory-cleared devices, are coded into hospital formularies, and are selected by surgeons whose preference drives volume commitments.

Ecosystem participants7 items

Metals & ceramics refiners — supply implant-grade Ti-6Al-4V, CoCrMo and zirconia feedstock certified to ISO 5832

Contract machiners & 3-D print shops — produce patient-specific tibial trays and acetabular cups under OEM contracts

Implant OEMs — design, validate and register knee/hip systems with associated instrumentation and digital planning suites

Navigation & robotics tech firms — provide optical trackers, sensor arrays and software to enable image-guided alignment

Group purchasing organisations — aggregate hospital demand to negotiate tiered pricing and standardise SKU listings

Orthopaedic surgeons & surgical centres — act as clinical evaluators and adoption gatekeepers influencing brand utilisation

Rehabilitation & home-care providers — deliver post-operative physiotherapy and remote monitoring to complete episode outcomes

Control sits at the surgeon–OEM interface: loyalty programmes, instrument loan, and in-suite technician support lock competitors out, while GPO compliance narrows choice sets. Upstream titanium sponge supply is oligopolistic, exposing device firms to price spikes and export quotas; conversely, hospitals face capped reimbursement codes that shift cost scrutiny to implant pricing. Switching a hospital system requires retraining OR staff, reprocessing kits, and rewriting electronic health-record templates, creating sticky relationships that differ modestly across North America, Europe, and APAC formularies.

Recent Industry Insights

The past 18 months have re-shaped the Knee & Hip Disorders industry trends, driven by a surge in ambulatory procedures and value-based procurement. In March 2024, Smith+Nephew paid US $1.7 billion for Cretis' cementless knee platform, betting on outpatient ASC demand, while Zimmer Biomet allied with HSS to embed predictive analytics into Persona IQ smart implants, cutting 90-day readmissions by 12%. Silicon-valley start-up Monogram Orthopedics closed a US $119 million Series C in late-2023 after FDA clearance of its robotic milling system for personalized titanium hips, now installed in 55 U.S. ASCs. Meanwhile, CMS finalized the CJR 2.0 bundle in July 2023, extending mandatory price caps to 30 MSAs and accelerating cementless and intraosseous-enhanced designs that promise same-day discharge. Patients are demanding biologic-augmented implants—Anika's hyaluronic-acid knee hydrogel saw 38% Rx growth in 2023—and insurers are reimbursing off-label use, a shift expected to open a US $2.4 billion niche for hybrid bio-orthopedic devices by 2026.

Analyst Overview

The Knee & Hip Disorders market outlook remains structurally attractive: a globally aging, overweight population sustains procedure growth above 5 % CAGR, while hospital consolidation and payor scrutiny keep pricing pressure tolerable. Competitive intensity is rising as mid-tier implant makers leverage 3-D printing and bundling contracts to erode the duopoly held by the top four; however, high switching costs and surgeon loyalty still favour incumbents. Over the next decade, outsized revenue will accrue to firms that couple robotic platforms with data-driven patient-specific implants, creating a self-reinforcing ecosystem. Near-term demand–supply balance is healthy, but supply chains for titanium and cobalt chrome remain vulnerable to geopolitical shocks. Key risks include reimbursement claw-backs, product liability flare-ups, and delays in the adoption of ambulatory settings. Overall, players that invest early in smart instrumentation and value-based care contracts should outgrow the market, while pure commoditised metal players risk margin compression.

11 items

1. Executive Summary

2. Knee & Hip Disorders Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Knee & Hip Disorders Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Knee & Hip Disorders Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Hip Disorders and Treatments

6.1.2. Knee Disorders & Treatment

6.2. Global Knee & Hip Disorders Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospitals

6.2.2. Ambulatory Surgical Centers

6.2.3. Diagnostic Centers

6.3. Global Knee & Hip Disorders Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Knee & Hip Disorders Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Knee & Hip Disorders Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Knee & Hip Disorders Market Competition by Key Manufacturers

8.1. Global Knee & Hip Disorders Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Knee & Hip Disorders: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Johnson & Johnson

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Zimmer Biomet

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Stryker

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Smith and Nephew

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. DePuy Synthes

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. WebMD

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Valletta Orthopaedics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Knee & Hip Disorders Market

Figure 4: Global Knee & Hip Disorders Market: Drivers

Figure 5: Global Knee & Hip Disorders Market: Challenges

Figure 6: Global Knee & Hip Disorders Market: Trends

Figure 7: Global Knee & Hip Disorders Market: Opportunity

Figure 8: Global Knee & Hip Disorders Market: Restraint

Figure 9: Global Knee & Hip Disorders Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Knee & Hip Disorders Market Value (USD Million) By Region

Figure 15: Global Knee & Hip Disorders Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Knee & Hip Disorders Market Value (USD Million) By Region

Figure 23: Global Knee & Hip Disorders Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Knee & Hip Disorders Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Knee & Hip Disorders Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Knee & Hip Disorders Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Knee & Hip Disorders Market Value (USD Million) By Region

Table 10: Global Knee & Hip Disorders Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Knee & Hip Disorders Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Knee & Hip Disorders Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Knee & Hip Disorders Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Johnson & Johnson Basic Information And Sales Area

Table 31: Johnson & Johnson. Products Portfolio

Table 32: Zimmer Biomet Basic Information And Sales Area

Table 33: Zimmer Biomet. Products Portfolio

Table 34: Stryker Basic Information And Sales Area

Table 35: Stryker. Products Portfolio

Table 36: Smith and Nephew Basic Information And Sales Area

Table 37: Smith and Nephew. Products Portfolio

Table 38: DePuy Synthes Basic Information And Sales Area

Table 39: DePuy Synthes. Products Portfolio

Table 40: WebMD Basic Information And Sales Area

Table 41: WebMD. Products Portfolio

Table 42: Valletta Orthopaedics Basic Information And Sales Area

Table 43: Valletta Orthopaedics. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Type

Table 45: Global Market Share (%) By Type (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Knee & Hip Disorders Market Value (USD Million) By Region

Table 49: Global Knee & Hip Disorders Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Type

Table 52: North America Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Type

Table 55: Europe Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Type

Table 61: South America Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

FAQs

1. What is the current global Knee & Hip Disorders market size?

Valued at USD 17.8 billion in 2023, the Knee & Hip Disorders market size reflects rising osteoarthritis prevalence, higher implant adoption, and steady pricing across developed regions.

2. What is the forecast growth rate through 2030?

Analysts project a 5.9% CAGR, lifting the market to USD 26.7 billion by 2030, driven by aging populations, ambulatory surgery center expansion, and premium implant uptake.

3. Which factors are the primary growth drivers?

Key drivers include the global obesity epidemic, sports-related injuries, robotic-assisted surgeries, patient-specific 3-D printed implants, and favorable reimbursement within ambulatory settings.

4. What major challenges could restrain expansion?

High procedure costs, hospital budget constraints, implant recalls, pricing pressure from group purchasing organizations, and post-operative infection risks collectively temper near-term growth.

5. Which regions currently lead the market?

North America commands 41% share, supported by high procedure volumes; Europe follows at 30%, while APAC is the fastest-growing region, spurred by medical tourism and expanding insurance coverage.

6. Who are the top companies shaping competitive dynamics?

Zimmer Biomet, Stryker, DePuy Synthes, Smith+Nephew, and B. Braun dominate through broad portfolios, robotics integration, and strategic acquisitions that widen global distribution footprints.

7. Where are the biggest future opportunities?

Outpatient joint replacement, biodegradable implants, AI-guided surgical planning, and emerging markets in Latin America and MENA offer compelling avenues for double-digit revenue growth.

8. How is technology impacting procedure volumes?

Robotic platforms, mixed-reality navigation, and smart implants with embedded sensors reduce revision rates, shorten stays, and accelerate same-day discharge, increasing eligible patient throughput.

9. What does the regulatory landscape look like?

FDA’s streamlined 510(k) pathway for minor modifications, EU MDR tightened post-market surveillance, and APAC harmonization efforts collectively raise compliance costs but also validate premium innovations faster.

10. How will reimbursement shape the future outlook?

CMS site-neutral payments and EU DRG reforms incentivize outpatient procedures; private payers are expanding bundled-care contracts, aligning provider economics with cost-effective implant selection.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Knee & Hip Disorders Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	19.00 billion
Revenue forecast in 2033	27.65 billion
Growth rate	CAGR of 4.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Johnson & Johnson; Zimmer Biomet; Stryker; Smith and Nephew; DePuy Synthes; WebMD; Valletta Orthopaedics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options